NCT01872026已完成1 期
ASP7991 Clinical Pharmacological Study -Examination of Pharmacokinetics and Pharmacodynamics in Chronic Kidney Disease Patients Undergoing Hemodialysis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 主要终点
- The safety of ASP7991 assessed by the incidence of adverse events, vital signs, laboratory tests, 12-lead ECGs, ECGs for QT evaluation and ophthalmic examination
研究概览
简要总结
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
详细描述
To examine the pharmacokinetics, pharmacodynamics and safety in patients with chronic kidney disease undergoing hemodialysis.
- To assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and the effect of hemodialysis on PK of single oral administration of ASP7991 in Part 1.
- To assess the safety, PK and PD of repeated oral administration of ASP7991 in part 2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients on stable chronic maintenance dialysis who are receiving hemodialysis therapy 3 times/week for more than 12 weeks (84 days) and are also scheduled to undergo the regimen of 3 times/week hemodialysis during the study period
- •Patients who have secondary hyperparathyroidism;
- •Receiving Active vitamin D or Cinacalcet hydrochloride
- •OR iPTH values ≥ 180 pg/mL at screening in case patients receive no medication for secondary hyperparathyroidism.
- •Corrected serum Ca at screening：≥ 8.4 mg/dL
- •No changes in items below at least 7 days before screening and do not have a plan to change something in the items below during the trial.
- •Dose and type of Active Vitamin D, Calcitonin preparation, Phosphate binder.
- •Ca concentration of the dialysate, membrane area of the dialyzer and dialysis time of each week(possible to change within ±10%)
排除标准
- •Patients who underwent parathyroid intervention within 24 weeks prior to the informed consent
- •Patients who have primary hyperparathyroidism
- •Having a history of gastric/intestinal resection considered influential on the absorption of the drug in the gastrointestinal tract
- •Patients with uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 120 mmHg are showed at the previous three points at the initiation of dialysis including the screening assessment)
- •Complicated by severe heart disorder [congestive cardiac failure (NYHA classification III or higher), or wide range of old myocardial infarction], or having a history of hospitalization for cerebro-vascular disease or heart disorder within 12 weeks(84 days) before obtaining the informed consent.
- •Concurrent serious hepatic disease (acute and active chronic hepatitis, hepatic cirrhosis)
- •History of malignant tumor
- •History of serious drug allergy including anaphylactic shock
- •Potentially child-bearing, lactating, those who do not comply with the instructed contraceptive measures
- •Patients who were involved in an assessment of other clinical trial within 12 weeks(84 days) prior to the informed consent
- •Patients who is an employee of the sponsor, CRO, SMO, or sites related to the study.
- •Patients who have been judged ineligible to participate in the study by the investigator / sub investigator.
研究组 & 干预措施
Part 1- single administration
Experimental
The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
干预措施: ASP7991 (Drug)
Part 2- repeated administration
Experimental
The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
干预措施: ASP7991 (Drug)
结局指标
主要结局
The safety of ASP7991 assessed by the incidence of adverse events, vital signs, laboratory tests, 12-lead ECGs, ECGs for QT evaluation and ophthalmic examination
时间窗: For 9-16 days after dosing
次要结局
- Plasma concentrations unchanged drug; AUClast, AUCinf, AUC24h, Cmax, Ctrough, tmax, t1/2, CL/F, Vz/F(For 9-16 days after dosing)
- iPTH, wPTH, corrected serum Ca* (Serum Ca and Serum Alb), P(For 9-16 days after dosing)
研究者
相似试验
已完成
1 期
Multiple Oral Administration of ASP7991 to Non-elderly Male SubjectsHealthyPharmacokinetics of ASP7991NCT01872013Astellas Pharma Inc36
已完成
1 期
A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy VolunteersHealthyPharmacokinetics of ASP7991NCT01675518Astellas Pharma Inc56
已完成
2 期
Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT02529449Astellas Pharma Inc43
已完成
1 期
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese SubjectsHealthyPharmacokinetics of ASP1941NCT01373060Astellas Pharma Inc56
已完成
1 期
Single-Dose Safety Study of APD791 in Healthy VolunteersHealthyNCT00529646Arena Pharmaceuticals90